U.S. License Holder:
Hugel Inc.
Date of License:
February-29-2024
Last Update:
Sep-30-2024
FDA-Approved Indications
LETYBO (letibotulinumtoxina-wlbg) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.